President Trump on Thursday announced a drug pricing deal with Regeneron — the last of 17 manufacturers the administration pressured last year to commit to his "most favored nation" policy.
Why it matters: The deals with the other companies to lower certain drug prices are being touted as one of the administration's signature health accomplishments, though Democrats question whether the confidential arrangements are really helping consumers.
